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Abstract
Introduction: Natural herbal compounds with novel actions different from existing breast cancer (BCa) treatment
modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-
O-galloyl-b-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through inhibiting DNA
replicative synthesis and G1 arrest, in addition to inducing cell death at higher levels of exposure. We and others
have shown that PGG through intraperitoneal (i.p.) injection exerts a strong in vivo growth suppression of human
PCa xenograft models in athymic nude mice. This study aims to test the hypothesis that the novel targeting
actions of PGG are applicable to BCa cells, especially those lacking proven drugable targets.
Methods: Mono-layer cell culture models of p53-wild type estrogen receptor (ER)-dependent MCF-7 BCa cells and
p53-mutant ER-/progesterone receptor (PR)- and Her2-regular (triple-negative) MDA-MB-231 BCa were exposed to
PGG for a comprehensive investigation of cellular consequences and molecular targets/mediators. To test the in
vivo efficacy, female athymic mice inoculated with MDA-MB-231 xenograft were treated with 20 mg PGG/kg body
weight by daily gavage starting 4 days after cancer cell inoculation.
Results: Exposure to PGG induced S-phase arrest in both cell lines as indicated by the lack of 5-bromo2’-deoxy-
uridine (BrdU) incorporation into S-phase cells as well as G1 arrest. Higher levels of PGG induced more caspase-
mediated apoptosis in MCF-7, in strong association with induction of P53 Ser
15 phosphorylation, than in MDA-MB-
231 cells. The cell cycle arrests were achieved without an induction of cyclin dependent kinase (CDK) inhibitory
proteins P21
Cip1 and P27
Kip1. PGG treatment led to decreased cyclin D1 in both cell lines and over-expressing
cyclin D1 attenuated G1 arrest and hastened S arrest. In serum-starvation synchronized MCF-7 cells, down-
regulation of cyclin D1 was associated with de-phosphorylation of retinoblastoma (Rb) protein by PGG shortly
before G1-S transition. In vivo, oral administration of PGG led to a greater than 60% inhibition of MDA-MB231
xenograft growth without adverse effect on host body weight.
Conclusions: Our in vitro and in vivo data support PGG as a potential drug candidate for breast cancer with novel
targeting actions, especially for a triple negative BCa xenograft model.
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Breast cancer (BCa) is the major cause of cancer-related
deaths for women in the US [1] and other Western
countries. Approximately 60% to 70% of BCa cases
express estrogen receptors (ERs) or progesterone recep-
tors (PRs) or both, and another approximately 20% of
cases have amplified HER-2 proto-oncogene and express
high levels of the HER-2 protein [2]. Approximately 15%
to 20% of BCa cases are in the category of triple-nega-
tive phenotype because of their lack of ER and PR and
do not have amplification of HER-2 [2,3]. These patients
have a very poor prognosis because, unlike the situation
for other types of BCa, there is no clinically validated,
molecularly targeted therapy. When surgical and radia-
tion options are no longer applicable to these triple-
negative patients, treatment with available cytotoxic and
genotoxic chemotherapy drugs produces limited efficacy
and significant side effects. There remains a strong and
urgent need for safer anti-cancer compounds for the
treatment/management of the triple-negative BCa and
its metastasis. Novel agents with multiple targeting abil-
ity distinct from the known drugable targets could be
useful for circumventing the limitations of current treat-
ment options.
Penta-1,2,3,4,6-O-galloyl-b-D-glucose (PGG) is a natu-
rally occurring gallotannin polyphenolic compound in
Oriental herbs such as Galla Rhois, the gallnut of Rhus
chinensis Mill, and the root of peony Paeonia suffruti-
cosa Andrews [4]. A couple of earlier papers have exam-
ined the in vitro effects of PGG while using an ER
+
estrogen-dependent and p53-wild-type MCF-7 BCa cell
culture model [5,6]. Chen and colleagues [5] reported
that PGG induced G1 arrest in association with upregu-
lated abundance of cyclin-dependent kinase inhibitor
(CDKI) proteins 1A (p21
Cip1) and 1B (p27
Kip1). Later,
the same group showed that PGG decreased ERa and
the HER family of membrane tyrosine kinase (EGFR,
HER-2, and HER-3) and PI3K/AKT signaling in MCF-7
cells [6]. A close inspection of the experimental designs
of these studies revealed a lack of critical time-matched
controls, and therefore the conclusions and the validity
of the mechanistic work reported are questionable.
In cell culture studies, we recently showed that PGG
induces caspase-mediated apoptosis in the human
LNCaP prostate cancer (PCa) cells that express wild-
type p53 [7]. The caspase-mediated apoptosis induction
by PGG was mediated in large part by activation of p53
as established through siRNA (small interference RNA)
knockdown and dominant negative mutant approaches
[7]. More recently, we showed the induction of cell
death with autophagic features (e.g., autophagosome for-
mation and addition of a phosphatidylethanolamine
moiety to the microtubule-associated protein 1 light
chain 3 [LC3] to a faster moving LC3-II form on elec-
trophoresis) by PGG of p53-null, PTEN-null, (high
AKT) PC-3 PCa cells, which did not undergo caspase-
mediated apoptosis after exposure to PGG [8]. We have
also investigated the cell cycle effects of PGG in these
and other PCa cells [9]. We showed for the first time
that, irrespective of the p53 and androgen dependence
status of the PCa cell lines, PGG exerted a rapid (within
2 hours) and potent (IC50 [half inhibitory concentration]
of approximately 6 μM) inhibition of 5-bromo-2’-deoxy-
uridine (BrdU) incorporation into S-phase cells. In iso-
lated nuclei, PGG inhibited DNA replicative synthesis
with an efficacy superior to that of a known DNA poly-
merase-alpha inhibitor, aphidocolin. We have found, in
addition to the S-arrest action, a close association of
downregulation of cyclin D1 with G1 arrest induced by
PGG. Taken together, our data with PCa cells indicate
that PGG induced S arrest, probably through DNA
replicative blockage, and induced G1 arrest via cyclin D1
downregulation to contribute to its anti-cancer activity.
These results sharply contrasted with the questionable
BCa cell culture studies mentioned above [5,6]. There-
fore, whether the S and G1 cell cycle arrests and cas-
pase-mediated or autophagic cell death actions of PGG
are applicable to BCa cells needs to be experimentally
tested.
In addition to PCa cells, PGG was shown to induce G1
cell cycle arrest and apoptosis of leukemia [10,11] to
inhibit invasion-related molecules such as matrix metal-
loprotease-9 in melanoma cells [12] and EGFR signaling
[13] and VEGFR2 signaling and angiogenesis in vitro
and in vivo [14], supporting multiple targeting actions.
An u m b e ro fin vivo studies by us and others in Lewis
lung cancer allograft [14] and PCa xenograft [7,13] mod-
els with a dose of 20 or 25 mg/kg every other day have
shown anti-cancer efficacy without adverse effect on
body weight. These in vivo and in vitro studies suggest
probable anti-cancer activity of PGG against BCa, espe-
cially triple-negative BCa. In this report, we evaluated
the cell cycle and cell death actions of PGG against
MDA-MB231 triple-negative BCa cells and MCF-7 BCa
cells, and we established, for the first time, an impress-
ive oral efficacy of PGG against xenograft growth estab-
lished from human MDA-MB231 cells.
Materials and methods
Chemicals and reagents
PGG was prepared in-house by methanolysis of tannic
acid in accordance with a published method [4,15]. The
purity was approximately 99%. For treatment of cells in
mono-layer culture, PGG was dissolved in dimethyl sulf-
oxide (DMSO) as a stock solution. The final DMSO
added to cell culture medium was below 0.1%. Antibo-
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Cip1, anti-P27
Kip1,
and anti-ERa, were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). Additional antibo-
dies specific for cleaved poly-ADP-ribose polymerase
(cPARP) (p89), cyclin D1, p53-Ser
15P, pRb-Ser
795,p R b -
Ser
807/811, and pAKT(Ser
473) were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). Anti-
body for LC-3 was purchased from MBL International
(Woburn, MA, USA).
Cell culture and treatments
MCF-7 and MDA-MB231 cell lines were purchased
from the American Type Culture Collection (Manassas,
VA, USA). No cell line was derived directly from human
tumor tissue for the purposes of this study. MCF-7 cells
were grown in RPMI-1640 medium supplemented with
10% fetal bovine serum (FBS) without antibiotics in an
i n c u b a t o ra t3 7 ° Cw i t h5 %C O 2. MDA-MB231 cells
were grown in L-15 medium supplemented with 10%
FBS without antibiotics in an incubator at 37°C with
atmospheric CO2. At 24 hours after plating, the medium
was changed before starting the treatment with PGG or
the other agents. To standardize all PGG/drug exposure
conditions, cells were bathed in culture medium at a
volume-to-surface area ratio of 0.2 mL/cm
2 (for exam-
ple, 15 mL for a T75 flask and 5 mL for a T25 flask).
Cell growth assay by crystal violet staining
For the evaluation of the overall inhibitory effect of
PGG on cell number, the cells were treated with PGG
daily (fresh medium) for 3 days. After treatment, the
culture medium was removed and the cells were fixed
in 1% glutaraldehyde solution in phosphate-buffered sal-
ine for 15 minutes. The fixed cells were stained with
0.02% aqueous solution of crystal violet for 30 minutes.
After the washing with phosphate-buffered saline, the
stained cells were solubilized with 70% ethanol. The
absorbance at 570 nm with the reference filter at 405
nm was evaluated using a microplate reader (Beckman
Coulter, Inc., Brea, CA, USA).
BrdU incorporation and cell cycle measurement
The protocol was based on our previous publications
[9,16]. After the desired experimental treatments, 10 μL
of BrdU (9 mg/mL) solution was added to 5 mL of med-
ium for 30 minutes before harvesting cells. The cells
were collected by trypsinization, centrifuged at 1,600g
for 6 minutes, fixed with 70% ethanol overnight, and
analyzed for cell cycle distribution by propidium iodide/
BrdU bivariate flow cytometry.
Synchronic MCF-7 cell G0/G1 progression model
MCF-7 cells were seeded in RPMI-1640 medium supple-
mented with 10% FBS without antibiotics in an
i n c u b a t o ra t3 7 ° Cw i t h5 %C O 2. Twenty-four hours
later, the cells were washed with serum-free phenol-red-
free RPMI-1640 medium and then incubated in serum-
free phenol-red-free medium for another 24 hours. One
flask of cells was reserved as 0-hours baseline control.
For the other flasks, serum-free medium was replaced
with complete medium (10% FBS) to release cells from
G0 arrest. At selected time points, cells were harvested
for flow cytometry to analyze cell cycle distribution. For
PGG treatment, cells were released into complete med-
ium and treated simultaneously with serum stimulation
or were exposed to PGG after different time periods of
G1 progression until 24 hours, when the cells were col-
lected for cell cycle analyses.
Immunoblot analyses
The cell lysate was prepared in ice-cold lysis buffer as
described previously [17]. Immunoblot analyses were
essentially as described [17], except that the signals were
detected by enhanced chemofluorescence with a Storm
840 scanner (Molecular Dynamics, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK).
MDA-MB231 xenograft model
The animal use protocol was approved by the Kyung
Hee University Institutional Animal Care and Use Com-
mittee and carried out at the Cancer Preventive Mate-
rial Development Research Center, College of Oriental
Medicine, Kyung Hee University (Seoul, South Korea).
One million MDA-MB231 cells were mixed with 50%
Matrigel (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA) and injected (in 100 μL) subcuta-
neously into the right flank of each 6-week-old female
BALB/c athymic nude mouse (NARA Biotech, Deajon,
South Korea). Starting 4 days after inoculation, 10 mice
per group were given a daily gavage treatment of 2%
Tween-80 (vehicle) or 20 mg of PGG per kg body
weight. The dosage was based on our PCa xenograft
work [7] and lung cancer allograft work [14]. Tumors
were measured twice per week with a caliper, and
tumor volume was calculated using the following for-
mula: 1/2 (w1 × w2 × w2), where w1 represents the lar-
ger tumor diameter and w2 represents the smaller
tumor diameter.
Statistical analyses
Numerical data were expressed as mean ± standard
error or standard deviation (where noted). Statistical
analyses were carried out with GraphPad Prism (Graph-
Pad Software, Inc., San Diego, CA, USA) software, and a
P value of less than 0.05 was considered statistically sig-
nificant. The data were analyzed by analysis of variance
followed by Dunnett’s multiple comparison post tests or
other appropriate tests.
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PGG inhibited MCF-7 and MDA-MB231 breast cancer cell
growth and induced caspase-mediated and caspase-
independent cell death
To evaluate the growth inhibitory effect on estrogen-
dependent BCa cell line MCF-7 and the triple-negative
BCa cell line MDA-MB231, we exposed these cells to
daily changes of fresh complete medium with increasing
concentrations of PGG. After 3 days of daily exposure,
PGG decreased the number of MCF-7 and MDA-
MB231 cells in a dose-dependent manner, and the IC50
of PGG for both cell lines was lower than 12.5 μM (Fig-
ure 1a). The p53-wild-type MCF-7 cells were more sen-
sitive than the p53-mutant triple-negative MDA-MB231
cells to the growth suppression action of PGG at each
tested concentration of PGG.
T h ed i f f e r e n c ei ns e n s i t i v i t yo ft h et w oB C ac e l ll i n e s
was associated in part with the propensity for MCF-7
cells to undergo caspase-mediated apoptosis preceded
by P53-Ser
15 phosphorylation (P53-Ser
15P) (24 hours)
and cleavage of PARP (48 hours) (Figure 1b). In the
MDA-MB231 cells, whose mutant P53 phosphorylation
was not responsive to PGG treatment, minimal cleavage
of PARP (72 hours) was preceded by autophagic features
as indicated morphologically by cytosolic vacuolation
(48 hours); biochemically by an early (6 hours) increase
of phosphorylation of AMPK (AMP-activated protein
kinase), a well-known autophagy signaling kinase in
response to nutrient deprivation [18]; and by increased
phosphatidylethanolamine modification of the microtu-
bule-associated protein 1 light chain 3 (LC3-I) to the
faster moving LC-3II form (24 to 48 hours) (Figure 1b).
These results therefore mirror our data (on PGG induc-
tion of apoptosis and other types of cell death) obtained
with LNCaP [7] and PC-3 PCa [8] cells, respectively.
PGG induced S and G1 arrests in MCF-7 and MDA-MB231
cells
Prompted by our findings of G1 and S arrests in differ-
ent PCa cell lines (LNCaP, DU-145, and PC-3) [8,9],
which contrasted with the reported G1 arrest in MCF-7
cells [5], we measured the cell cycle distribution patterns
of MCF-7 and MDA-MB231 cells after exposure in
complete medium to different concentrations of PGG
for 6, 24, and 48 hours.
In both MCF-7 and MDA-MB231 cells, PGG exposure
for 6 hours led to a concentration-dependent increase of
G1-phase cells and was accompanied by a decrease of
G2-phase cells (Figure 2). Probably owing to their faster
growth, the MB231 cells (Figure 2b) appeared to more
readily achieve G1 arrest than the MCF-7 cells (Figure
2a) in the presence of the lowest PGG concentration
tested. The percentage of S-phase cells remained
relatively steady in both cell lines. Inspection of the
BrdU incorporation index (measured, as we previously
described, for 30 minutes of pulse labeling before cell
harvest [9]) showed a near-complete blockage of DNA
synthesis in the S-phase cells in MB231 cells at all three
PGG exposure concentrations, whereas in the MCF-7
cells, a clear concentration dependency on PGG was
observed.
For both cell lines, as time progressed to 24 and 48
hours, the lowest concentration of PGG (12.5 μM) was
not able to hold the cells arrested in G1, manifesting as
the accumulation of S-phase cells that remained incap-
able of incorporating BrdU. The higher concentrations
of PGG (50 μM) kept cells arrested in G1 phase and S
phase throughout the 6- to 48-hour period (Figure 2).
The data therefore support both S arrest and G1 arrest
by PGG in BCa cells, as in PCa cells [9].
PGG did not alter P21
Cip1 and P27
Kip1 expression in
breast cancer cells
An earlier report by Chen and colleagues [5] has
claimed G1 arrest and P21
Cip1 and P27
Kip1 induction by
PGG in MCF-7 cells, without including critical time-
matched controls. We therefore examined these proteins
as possible molecular mediators for the G1 and S arrests.
S i n c ew eh a v er e p o r t e dt h er a p i dP 5 3 - S e r
15Pb yP G G
treatment in LNCaP PCa cells [7] and have observed
P53-Ser
15P in PGG-exposed MCF-7 cells (Figure 1b)
and since the P53-P21
Cip1 axis is best known for mediat-
ing G1 arrest by genotoxic stress [19], we focused on the
relationship among these proteins in PGG-exposed
MCF-7 cells.
We observed that PGG treatment activated P53-Ser
15P
at 6 hours with a clear concentration dependency but
did not increase the protein abundance of either P21
Cip1
or P27
Kip1 (Figure 3a). Later, we found the same pattern
of disengaged P53/P21
Cip1 response (that is, P53-Ser
15P
but not upregulated P21
Cip1) in the synchronic MCF-7
model (Figure 4). In MDA-MB231 cells, we did not
observe any induction of these two CDKI proteins by
PGG (Figure 3b). These results suggest that PGG
induced G1 arrest in the absence of detectable altera-
tions of P21
Cip1 and P27
Kip1 protein abundance and was
independent of P53 function in these BCa cells.
PGG decreased cyclin D1 abundance in breast cancer cells
In contrast to a lack of expression change of P21
Cip1 or
P27
Kip1, PGG treatment significantly decreased the
abundance of cyclin D1 in MCF-7 and MDA-MB231
cells (Figure 3a, c). PGG treatment decreased cyclin D1
expression as early as 6 hours, and by 12 hours, its
expression decreased dramatically. From 24 to 48 hours,
there was almost no detectable cyclin D1 expression in
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high dose (Figure 3a, c).
To test the contribution of cyclin D1 downregulation
to the G1 arrest, we made stable transfectants of MCF-7
and MDA-MB231 cells with forced overexpression of
cyclin D1 (Figure 5a) (the expression plasmid was kindly
provided by Joshua D Liao, The Hormel Institute, Aus-
tin, MN, USA). Compared with vector transfectant cells,
the cyclin D1-overexpressing MCF-7 cells significantly
attenuated PGG-induced G1 arrest (Figure 5b). Similarly,
Figure 1 Growth inhibitory and cell death actions of PGG in MCF-7 and MDA-MB231 cells. (a) Overall inhibitory effects of PGG on MCF-7
and MDA-MB231 cell growth after 3 days of daily treatment with PGG in fresh medium. Values are mean ± standard error of the mean (n =3
wells of 12-well plate). Statistical significance: ***P < 0.001; ****
,####P < 0.0001 versus untreated control. Results are representative of two
independent experiments. (b) Immunoblot detection of apoptotic cPARP (cleaved poly-ADP-ribose polymerase), P53-Ser
15 phosphorylation
induced by PGG in MCF-7 or MDA-MB231 cells, and autophagy responses (pAMPK and LC3-II) in MDA-MB231 cells. Phase-contrast
photomicrograph shows vaculolation typical of autophagy. The medium was not changed for PGG exposure of longer than 24 hours. DMSO,
dimethyl sulfoxide; LC3, microtubule-associated protein 1 light chain 3; pAMPK, phospho-AMP kinase; PGG, penta-O-galloyl-b-D-glucose.
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overcame PGG-induced G1 arrest (Figure 5c). Instead,
PGG exposure of the cyclin D1-overexpressing cells has-
tened S arrest, without affecting G2-phase decline. The
data suggest that G1 arrest and S arrest operate by inde-
pendent mechanisms in BCa cells, as in PCa cells [9],
and that cyclin D1 downregulation by PGG was an
important contributor (but perhaps not the sole media-
tor) to G1 arrest.
Defining G1-targeting action of PGG in a synchronic MCF-
7 model
To further probe the G1-targeting mechanisms of action
of PGG without the complication from S arrest, we
synchronized MCF-7 cells to G0 by serum starvation for
24 hours and released the cells into complete medium
(this time point was referred to as 0 hours). Cell cycle
distribution patterns suggested that the G1-phase cells
started to transit into S phase between 20 and 22 hours
of FBS re-stimulation (Figure 6a).
In this synchronic MCF-7 cell model, inclusion of
PGG at the time of serum stimulation (PGG@0 hours)
caused a complete block of G1-to-S transition, measured
by flow cytometry at 24 hours (Figure 6b). To determine
whether the presence of PGG during the early stage G0/1
progression was necessary for G1 arrest and to pin-
point the responsible molecular events, we delayed the
starting time for PGG exposure in reference to serum
Figure 2 The effect of PGG on cell cycle distribution of MCF-7 (a) and MDA-MB231 (b) cells detected by propidium iodide/BrdU-
bivariate flow cytometric analyses. Cells were exposed to increasing concentrations of PGG for 6, 24, and 48 hours. BrdU was added for the
last 30 minutes to label S-phase cells active in DNA replication. Values are mean ± standard error of the mean (n = 4). Results are from two
independent experiments with duplicate values at each concentration. The medium was not changed for PGG exposure of longer than 24
hours. Statistical significance: (a) BrdU incorporation at all three time points, one-way analysis of variance (ANOVA) P < 0.0001, with Dunnett’s
multiple comparison post test P value of less than 0.01 for 0 versus 12.5, 25, and 50 μM PGG. For G1, 6 hours P < 0.05 for 0 versus 25 and 50 μM
PGG; 24 hours P < 0.01 for 0 versus 12.5 or 50 μM PGG; 48 hours P < 0.01 for 0 versus 12.5 μM PGG and P < 0.05 for 0 versus 50 μM PGG. For S,
24 hours/48 hours P < 0.01 for 0 versus 12.5 and 25 μM PGG. (b) BrdU incorporation at all three time points, one-way ANOVA P < 0.0001, with
Dunnett’s multiple comparison post test P value <0.01 for 0 versus 12.5, 25, and 50 μM PGG. For G1, 6 hours P < 0.05 for 0 versus 12.5, 25, and
50 μM PGG; 24 hours P < 0.01 for 0 versus 25 and 50 μM PGG; 48 hours P < 0.01 for 0 versus 50 μM PGG. For S, 24 hours/48 hours P < 0.01 for
0 versus 12.5 μM PGG. BrdU, 5-bromo-2’-deoxy-uridine; PGG, penta-O-galloyl-b-D-glucose.
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i n ge x p o s u r et i m et o1 4h o u r s( t h a ti s ,P G G @ 1 4
hours) did not lessen the G1-arrest action of PGG.
Starting PGG treatment at 16 to 18 hours was less
able to prevent G1-to-S transition. These data indicated
that the crucial time window for PGG targeting during
G1/S progression was 16 to 18 hours after serum
stimulation.
PGG decreased cyclin D1 in synchrony with
retinoblastoma de-phosphorylation in synchronic MCF-7
cells
In the synchronic MCF-7 model, serum stimulation led
to increased cyclin D1 expression (4 hours was the
earliest point sampled), which persisted through 20
hours (G1/S transit) (Figure 4). Serum stimulation
increased survival signaling, as indicated by AKT phos-
phorylation, in a temporal pattern similar to that of
cyclin D1 and suppressed background level apoptosis as
indicated by the decreased cPARP. Serum stimulation
decreased ERa, which declined progressively over time.
A well-known downstream effector molecule of cyclin-
CDK complexes for G1 progression is the retinoblas-
toma (Rb) protein [20]. Cyclin-CDK complexes phos-
p h o r y l a t eR bt od e c r e a s ei t sb i n d i n gt ot h eE 2 F
transcriptional factor, releasing E2F to activate expres-
sion of its target genes for G1/S transition. Indeed, we
detected increased Rb phosphorylation at 12 hours at
the Ser
795 site and 16 hours at Ser
807/811 sites prior to
the onset of G1/S transition (20 hours).
Exposure of synchronic MCF-7 cells to PGG at the
time of serum stimulation did not decrease cyclin D1
until 16 hours, coinciding with decreased Rb phosphory-
lation at Ser
795 and Ser
807/811 sites (Figure 4). Although
P53-Ser
15P was detected by 8 hours of PGG treatment,
there was a clear absence of P21
Cip1 induction by PGG
throughout 20 hours. Increased cPARP was detected by
16 hours, and this was preceded by increased AKT
(Ser
473) phosphorylation by several hours. PGG treat-
ment did not affect ERa until the 20-hour time point.
Given that P21
Cip1 abundance was not upregulated
Figure 3 Effect of PGG on cyclin D1, P21
Cip1,a n dP 2 7
Kip1 and
other select cell cycle proteins in MCF-7 and MDA-MB231 cells
detected by Western blot analyses. (a) Cyclin D1, CDK4, P21
Cip1,
and P27
Kip1 expression and P53-Ser
15P in MCF-7 cells. b-Actin was
re-probed as loading control. (b) P21
Cip1 and P27
Kip1 expression in
MDA-MB231 cells. (c) Time course of cyclin D1 expression in MCF-7
and MDA-MB231 cells treated with PGG from 12 to 48 hours.
Patterns are representative of two experiments. The medium was
not changed for PGG exposure of longer than 24 hours. P21
Cip1,
cyclin-dependent kinase inhibitor 1A; P27
Kip1, cyclin-dependent
kinase inhibitor 1B; PGG, penta-O-galloyl-b-D-glucose.
Figure 4 The effect of PGG on cell cycle proteins in serum
starvation-synchronized MCF-7 cells. PGG was included at time
of serum stimulation (as time 0). Western blot was used to detect
Cyclin D1 expression and phosphorylation of Retinoblastoma
protein, activation of P53-Ser
15P, and expressions of P21
Cip1 and
estrogen receptor-alpha. cPARP, cleaved poly-ADP-ribose
polymerase; ERa, estrogen receptor-alpha; FBS, fetal bovine serum;
P21
Cip1, cyclin-dependent kinase inhibitor 1A; PGG, penta-O-galloyl-
b-D-glucose.
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the G1 arrest was regulated predominantly by the cyclin
D-CDK-Rb axis, preventing the release of E2F to pro-
mote the passage of the restriction point.
Orally administered PGG suppresses MDA-MB231 breast
cancer xenograft growth
The cell culture data presented above suggest probable
in vivo anti-cancer efficacy of PGG against BCa growth.
Because oral administration is the most practical and
non-invasive way to deliver an anti-cancer agent, we
evaluated the efficacy of PGG delivered by oral gavage
against MDA-MB231 cells injected subcutaneously into
the right flank of each female athymic nude mouse at
the dosage of 20 mg/kg body weight, starting 4 days
after cancer cell inoculation. This dosage of PGG did
not exert any adverse effect on body weight of the host
nude mice (Figure 7a). PGG treatment led to a signifi-
cant inhibition of tumor growth rate over time (Figure
7b) and decreased the final tumor size by over 60% at
necropsy.
Discussion
As pointed out in the Introduction, there is an urgent
clinical need for safe and effective treatment and pre-
ventive agents for triple-negative BCa. Our results pre-
sented above provide in vitro and in vivo data that
support the potential for PGG to be such a promising
drug candidate with multiple targeting actions, distinct
from known drugable BCa targets such as the ER (for
example, estrogen antagonist drug tamoxifen) and HER-
2 (for example, inactivating monoclonal antibody her-
ceptin). In cell culture, PGG treatment caused P53-Ser
15
phosphorylation (Figures 1, 3, and 4) and caspase-
mediated apoptosis (Figures 1 and 4) in MCF-7 BCa
cells. In p53-mutant MDA-MB231 triple-negative BCa
cells, PGG caused not only apoptosis but also autopha-
gic responses (Figure 1b).W es h o w e dt h a ti n d e p e n -
dently of P53 status or ERa status of the BCa cells,
PGG induced S arrest and G1 arrest (Figure 2) without
inducing P21
Cip1 and P27
Kip1 expression (Figures 3 and
4). Our data support cyclin D1 downregulation by PGG
as an important mediating event for the G1-arrest action
(Figures 3 to 5). The clear disengagement of P53-Ser
15
phosphorylation from the best-known P53 transcrip-
tional target P21
Cip1 in PGG-exposed MCF-7 cells
remains an interesting question for further investigation.
Our findings are important in two respects. First, they
are consistent with recently published results for PCa
cells [7-9], suggestive of a treatment applicability of
PGG for cancers of other organ sites. The documented
ability in this study to generate high-purity PGG in
multi-gram quantities from tannic acid will enable us
and others to explore the in vivo anti-cancer efficacy of
PGG in relevant animal models of cancers of other
organ sites. Second, the findings point out the possibility
that some published data are highly questionable con-
cerning the action mechanisms of PGG in BCa cells. In
contrast to the data published by others [5], our data
d i dn o td e t e c tac h a n g eo fP 2 1
Cip1 and P27
Kip1 expres-
sion to be associated with the G1-arrest action of PGG
(Figure 3). We also did not observe a dramatic impact
of PGG on ERa abundance or a suppression of AKT
phosphorylation (Figure 4), as were claimed [6]. Instead,
PGG treatment increased AKT phosphorylation in
Figure 5 Impact of overexpression of cyclin D1 on PGG-
induced G1 arrest in MCF-7 and MDA-MB231 cells. (a) Western
blot verification of stable overexpression of cyclin D1 in MCF-7 and
MDA-MB231 cells. (b) Cell cycle distribution of MCF-7 cells
transfected with vector and cyclin D1 plasmid with or without PGG
treatment for 24 hours. (c) Cell cycle distribution of MDA-MB231
cells transfected with vector and cyclin D1 plasmid with or without
PGG treatment for 24 hours. Each bar reflects the average of two
T25 flasks. The patterns are representative of two experiments. PGG,
penta-O-galloyl-b-D-glucose.
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increase of AKT phosphorylation in PC-3 cells by PGG
[8]. Although many reasons could be cited for the dis-
crepancies between our data and the previous reports
[5,6], their lack of time-matched controls could be the
leading cause of confusion and misleading conclusions.
Our in vivo data demonstrated, for the first time, a
growth inhibitory efficacy of PGG against triple-negative
BCa and supported the oral bioavailability of PGG. The
potency of PGG (20 mg per kg body weight) is remark-
able, especially considering that PGG was given by the
oral route. Furthermore, just the fact that PGG is orally
available and therefore can be self-administered by
Figure 6 Effect of PGG on G0/1-S progression in synchronized MCF-7 cells. (a) The temporal kinetics of serum-stimulated progression of
starvation-synchronized MCF-7 cells. Each time point was the average of duplicate flasks. *
,#P < 0.05; **
,##P < 0.01; ***
,###P < 0.001 versus 0 time.
(b) Impact of delaying PGG treatment with reference to serum stimulation on G1 arrest. Results are from two independent experiments with
duplicate values at each time point. *
,#P < 0.05; **
,##P < 0.01 versus serum-free (SF) or PGG@0h-14 h. CM, complete medium; PGG, penta-O-
galloyl-b-D-glucose.
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Page 9 of 11patients will have a major impact on reducing the
health-care delivery cost compared with injection-only
drugs (such as paclitaxel) that have to be given by
health-care professionals. The data on efficacy and safety
of PGG provide an impetus for further studies about the
therapeutic application of PGG and its in vivo molecular
targets and mechanisms of action.
Conclusions
Our cell culture data showed that PGG could induce
both G1 and S arrests in BCa cells, regardless of their ER
or P53 functional status. Cyclin D1 downregulation by
PGG was a mechanism for G1 arrest in BCa cell lines,
and the data ruled out P21
Cip1 and P27
Kip1 for mediating
G1 arrest. We demonstrated for the first time that PGG
given by oral administration was quite safe to the host
nude mice and potent for suppressing a triple-negative
BCa xenograft model. The therapeutic and chemopreven-
tive utility of PGG for BCa merits further study.
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